Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eton Pharmaceuticals, Inc. (ETON : NSDQ)
 
 • Company Description   
Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.90 Daily Weekly Monthly
20 Day Moving Average: 46,934 shares
Shares Outstanding: 25.50 (millions)
Market Capitalization: $99.47 (millions)
Beta: 1.44
52 Week High: $4.28
52 Week Low: $1.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.55% 5.40%
12 Week 0.78% -6.45%
Year To Date 38.30% 25.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21925 W. FIELD PARKWAY SUITE 235
-
DEER PARK,IL 60010
USA
ph: 847-787-7361
fax: -
investorrelations@etonpharma.com http://www.etonpharma.com
 
 • General Corporate Information   
Officers
Sean E. Brynjelsen - Chief Executive Officer;President and Director
James Gruber - Chief Financial Officer; Treasurer and Secretary
Jennifer M. Adams - Director
Charles J. Casamento - Director
Paul V. Maier - Director

Peer Information
Eton Pharmaceuticals, Inc. (CORR.)
Eton Pharmaceuticals, Inc. (RSPI)
Eton Pharmaceuticals, Inc. (CGXP)
Eton Pharmaceuticals, Inc. (BGEN)
Eton Pharmaceuticals, Inc. (GTBP)
Eton Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29772L108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/10/23
Share - Related Items
Shares Outstanding: 25.50
Most Recent Split Date: (:1)
Beta: 1.44
Market Capitalization: $99.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.85
Price/Cash Flow: -
Price / Sales: 4.08
EPS Growth
vs. Year Ago Period: 52.38%
vs. Previous Quarter: -350.00%
Sales Growth
vs. Year Ago Period: 143.75%
vs. Previous Quarter: -37.59%
ROE
03/31/23 - -52.12
12/31/22 - -70.91
09/30/22 - -64.18
ROA
03/31/23 - -27.16
12/31/22 - -38.89
09/30/22 - -37.36
Current Ratio
03/31/23 - 2.55
12/31/22 - 3.10
09/30/22 - 3.52
Quick Ratio
03/31/23 - 2.49
12/31/22 - 3.01
09/30/22 - 3.42
Operating Margin
03/31/23 - -26.05
12/31/22 - -42.45
09/30/22 - -47.19
Net Margin
03/31/23 - -26.05
12/31/22 - -42.45
09/30/22 - -47.19
Pre-Tax Margin
03/31/23 - -26.05
12/31/22 - -42.45
09/30/22 - -47.19
Book Value
03/31/23 - 0.44
12/31/22 - 0.52
09/30/22 - 0.44
Inventory Turnover
03/31/23 - 16.04
12/31/22 - 13.34
09/30/22 - 10.05
Debt-to-Equity
03/31/23 - 0.45
12/31/22 - 0.41
09/30/22 - 0.51
Debt-to-Capital
03/31/23 - 31.24
12/31/22 - 29.16
09/30/22 - 33.68
 

Powered by Zacks Investment Research ©